I
INFIRST LIMITED
infirst Ltd is a new company exclusively focusing on the rapid commercialisation and globalisation of Flarin® (patent protected lipid formulation of ibuprofen).
Country/Area ：United Kingdom
Company Email ：martyn.buckley@infirst.co.uk
Industry ：Manufacturing GeneralManufacturing
Company address ：Central Point, 45 Beech Street , EC2Y 8AD
Company website ：*****
Company phone ：+44 2071536600
Established ：2019-02-08
Company Revenue ：$4,166,000
Number of employees ：<25
SIC Code ：28283
NAICS Code ：32325
Company News
Carlin Consumer Health Acquires Infirst USA Holdings, LLC
Oct 24, 2023
NEW YORK--(BUSINESS WIRE)--Carlin Consumer Health (“Carlin”), a preeminent consumer health business that specializes in acquiring leading over the counter (“OTC”) brands, today announced that it has acquired Infirst USA Holdings, LLC (“Infirst”), the parent company of Infirst Healthcare Inc. Infirst is the marketer of two iconic digestive health brands, Mylanta® and Mylicon®, pursuant to a trademark licensing agreement with McNeil Consumer Pharmaceuticals Co. As part of the transaction, Infirst
Oct 24, 2023
InFirst names chief financial officer - NewsBreakFeb 19, 2022
The InFirst Bank executive team and board of directors recently announced that David Hudak has joined the bank as their new chief financial officer. In his 35 years of experience in the banking industry, Hudak has become well known for his professionalism and management skills. He has 25 years of experience...
Feb 19, 2022IW Capital leads second round of fundraising in Flarin to drive rapid commercialisation of world’s first lipid formulated ibuprofenApr 7, 2021
IW Capital leads second round of fundraising in Flarin to drive rapid commercialisation of world’s first lipid formulated ibuprofen Submitted 07/04/2021 - 10:38am Following the initial investment in 2019, IW Capital has led the second round of funding in Flarian, a patent protected lipid formulated ibuprofen which at a dose of 1200 mg/day has shown to be as effective as 2400mg/day of standard liquid ibuprofen capsules in patients with acute joint pain. Flarin’s unique lipid
Apr 7, 2021Web Summary
Q1: What is the company name and its type?
A1: The company name is Flarin Holdings Limited, which is an independent company dedicated to the progressive international commercialisation of Flarin.
Q2: What is Flarin?
A2: Flarin is the first and only lipid formulated ibuprofen analgesic, widely patented internationally and clinically proven to be as effective as twice the dose of standard ibuprofen.
Q3: What are the indications for Flarin 200 mg soft capsules?
A3: Flarin 200 mg soft capsules are indicated for a wide range of symptoms including relief of rheumatic pain or muscular pain, back pain, and non-serious arthritic conditions caused by swelling, stiffness, and inflammation.
Q4: Who are the current owners of Flarin Holdings Limited?
A4: The current owners of Flarin Holdings Limited include corporate shareholdings held by ITV plc, Hambro Perks Ltd, Biocopea Ltd, and a large number of private holdings including shareholders introduced by IW Capital Ltd.
Q5: What is the background of Manfred Scheske, Chairman of infirst Limited?
A5: Manfred Scheske has over 25 years of experience with GlaxoSmithKline Consumer Health, including presidency roles for Europe and North America. He was previously CEO of Infirst Healthcare Group and served as President of the Nuremberg Institute for Market Decisions.
Q6: Who is Philip Lindsell, Managing Director of Flarin Holdings Limited?
A6: Philip Lindsell joined Infirst Healthcare as Chief Financial Officer in November 2018 and was appointed Chief Financial Officer of Flarin Holdings Limited in October 2019 and Managing Director in 2023. He has over 30 years of experience as a chartered accountant.
Q7: What is the role of Alan Armstrong, Non-Executive Director?
A7: Alan Armstrong is a Non-Executive Director of Flarin Holdings Limited, working with the management team and managing IW Capital’s investment in the Company. He has over 30 years of experience as a private equity professional.
Q8: Who is Karen Stoner, Chief Scientific Officer?
A8: Karen Stoner has over 30 years of experience in leading drug development across a range of therapeutic areas, including women's health, endocrinology, osteoarthritis, respiratory, and urology. She began her career in clinical research and gained broad experience in pharmaceutical development.
Q9: What is the background of Martyn Buckley, Director of Sales & Marketing Activation?
A9: Martyn Buckley has 25 years of experience in Pharmaceutical, Consumer Healthcare, and FMCG, working with companies such as Novartis, Nutricia, and McCormick Foods. He has a background in business development and enablement.
Q10: Who is Karel Deckers, Director of Manufacturing & Sales?
A10: Karel Deckers had a 23-year career with GlaxoSmithKline and its legacy companies, being responsible for global external supplies before joining Infirst Healthcare.
A1: The company name is Flarin Holdings Limited, which is an independent company dedicated to the progressive international commercialisation of Flarin.
Q2: What is Flarin?
A2: Flarin is the first and only lipid formulated ibuprofen analgesic, widely patented internationally and clinically proven to be as effective as twice the dose of standard ibuprofen.
Q3: What are the indications for Flarin 200 mg soft capsules?
A3: Flarin 200 mg soft capsules are indicated for a wide range of symptoms including relief of rheumatic pain or muscular pain, back pain, and non-serious arthritic conditions caused by swelling, stiffness, and inflammation.
Q4: Who are the current owners of Flarin Holdings Limited?
A4: The current owners of Flarin Holdings Limited include corporate shareholdings held by ITV plc, Hambro Perks Ltd, Biocopea Ltd, and a large number of private holdings including shareholders introduced by IW Capital Ltd.
Q5: What is the background of Manfred Scheske, Chairman of infirst Limited?
A5: Manfred Scheske has over 25 years of experience with GlaxoSmithKline Consumer Health, including presidency roles for Europe and North America. He was previously CEO of Infirst Healthcare Group and served as President of the Nuremberg Institute for Market Decisions.
Q6: Who is Philip Lindsell, Managing Director of Flarin Holdings Limited?
A6: Philip Lindsell joined Infirst Healthcare as Chief Financial Officer in November 2018 and was appointed Chief Financial Officer of Flarin Holdings Limited in October 2019 and Managing Director in 2023. He has over 30 years of experience as a chartered accountant.
Q7: What is the role of Alan Armstrong, Non-Executive Director?
A7: Alan Armstrong is a Non-Executive Director of Flarin Holdings Limited, working with the management team and managing IW Capital’s investment in the Company. He has over 30 years of experience as a private equity professional.
Q8: Who is Karen Stoner, Chief Scientific Officer?
A8: Karen Stoner has over 30 years of experience in leading drug development across a range of therapeutic areas, including women's health, endocrinology, osteoarthritis, respiratory, and urology. She began her career in clinical research and gained broad experience in pharmaceutical development.
Q9: What is the background of Martyn Buckley, Director of Sales & Marketing Activation?
A9: Martyn Buckley has 25 years of experience in Pharmaceutical, Consumer Healthcare, and FMCG, working with companies such as Novartis, Nutricia, and McCormick Foods. He has a background in business development and enablement.
Q10: Who is Karel Deckers, Director of Manufacturing & Sales?
A10: Karel Deckers had a 23-year career with GlaxoSmithKline and its legacy companies, being responsible for global external supplies before joining Infirst Healthcare.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
